azetirelin

05/08/1989 - "In the present studies, the effect of YM-14673 was examined in rats following standardized traumatic brain or spinal cord injury. "
05/08/1989 - "TRH analog YM-14673 improves outcome following traumatic brain and spinal cord injury in rats: dose-response studies."
05/08/1989 - "Treatment with YM-14673 improved chronic neurological recovery after trauma in both injury models; optimal beneficial effects were found at a dose of 1.0 mg/kg. These findings confirm previous observations that TRH or TRH analogs may improve outcome after traumatic brain and spinal cord injury and are consistent with the hypothesis that TRH analogs preserving the C-terminus are effective in CNS trauma."
03/01/1994 - "Modeling of acute spinal cord injury in the rat: neuroprotection and enhanced recovery with methylprednisolone, U-74006F and YM-14673."
02/01/1993 - "A comparison of YM-14673, U-50488H, and nalmefene after spinal cord injury in the rat."

08/01/1989 - "Thus, YM-14673 improved behavioral response in a model of chronic focal cerebral ischemia. "
03/01/1989 - "YM-14673 mitigated the behavioral disturbances in this model of chronic focal cerebral ischemia. "
06/08/1990 - "Pharmacological actions of a new TRH analogue, YM-14673, in rats subjected to cerebral ischemia and anoxia."
03/01/1989 - "We observed the effects of a new thyrotropin-releasing hormone derivative, YM-14673 (N alpha-[[(S)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide dihydrate), on behavioral changes in rats for 3 weeks after focal cerebral ischemia. "
07/01/1989 - "The influence of YM-14673 (N alpha-[[(S)-4-oxo-2-azetidinyl]-carbonyl]-L-histidyl-L-prolinamide dihydrate), a new thyrotropin releasing hormone (TRH) analogue, on morphine-induced hypothermia, development of cerebral ischemia and analgesia was investigated in rodents. "

05/08/1989 - "Treatment with YM-14673 improved chronic neurological recovery after trauma in both injury models; optimal beneficial effects were found at a dose of 1.0 mg/kg. These findings confirm previous observations that TRH or TRH analogs may improve outcome after traumatic brain and spinal cord injury and are consistent with the hypothesis that TRH analogs preserving the C-terminus are effective in CNS trauma."
03/01/1994 - "We used a new injury device that produces consistent spinal cord contusion injuries (T8) in rats to compare the behavioral and histologic effects of methylprednisolone sodium succinate (MPSS) administration, the clinical standard of therapy after acute spinal cord injury (ASCI), with the 21-aminosteroid, U-74006F (U74), and the TRH analogue, YM-14673 (YM), at different trauma doses. "

01/01/1990 - "Therefore, YM-14673 may be beneficial for the treatment of several spinal motor neuron diseases."

01/01/1993 - "Thirty minutes following fluid-percussion brain injury of moderate severity, animals received an intravenous bolus of either naloxone (2.0 mg/kg with constant infusion of 1.7 mg/kg/h, n = 8), YM-14673 (1.0 mg/kg, n = 8), or saline (n = 8). "
01/01/1993 - "The present study evaluated the ability of the opiate antagonist naloxone hydrochloride to improve posttraumatic neurologic motor function following experimental fluid-percussion brain injury in the rat, and compared the therapeutic effectiveness of naloxone to the long-acting, centrally active TRH analog YM-14673. "
01/01/1993 - "Beneficial effect of the nonselective opiate antagonist naloxone hydrochloride and the thyrotropin-releasing hormone (TRH) analog YM-14673 on long-term neurobehavioral outcome following experimental brain injury in the rat."